Disclosure of director Clay Siegall's $250K stock purchase drives STTK's 15.79% gain
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.72M | $1.66M | $652.00K | $30.02M | $9.93M | $9.89M | $22.44M |
| Cost of Revenue | N/A | $4.04M | N/A | $1.38M | $37.48M | $29.22M | $24.81M |
| Gross Profit | $5.72M | $-2.38M | $652.00K | $28.64M | $-27.55M | $-19.33M | $-2.37M |
| Gross Margin | 100.00% | -143.93% | 100.00% | 95.40% | -277.32% | -195.52% | -10.54% |
| Operating Expenses | $86.29M | $89.57M | $103.98M | $73.91M | $9.38M | $5.74M | $3.78M |
| Operating Income | $-80.57M | $-91.96M | $-103.33M | $-45.27M | $-36.93M | $-25.07M | $-6.15M |
| Operating Margin | -1408.27% | -5549.61% | -15848.01% | -150.81% | -371.76% | -253.53% | -27.40% |
| Net Income | $-75.41M | $-87.30M | $-101.94M | $-44.97M | $-36.60M | $-23.98M | $-7.39M |
| Net Margin | -1318.13% | -5268.44% | -15635.74% | -149.83% | -368.46% | -242.56% | -32.92% |
| EPS (Basic) | $-1.49 | $-2.05 | $-2.41 | $-1.07 | $-0.88 | $-0.57 | $-0.49 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |